about us

press release

contact

Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

Past News

NeuroBo Pharmaceuticals Closes $14 Million Registered Direct Offering

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering

54gene Closes $25M Series B

The round also included participation from Adjuvant Capital, KdT Ventures, Plexo Capital, Endeavor Capital, Ingressive Capital and others.

Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases

Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies.

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline

Cytovia eligible for up to $400 million in licensing milestones for Greater China rights.vCoordinated US and China clinical development of GPC3-targeted therapies for hepatocellular carcinoma.

Locate Bio Closes £10 million Funding Round

Investors include Mercia Asset Management and BGF. Funding to further advance Locate Bio’s regenerative medicine pipeline of orthobiologics

Immunitas Therapeutics Completes $58 Million Series B Financing

Funding to advance novel NK and T cell modulator IMT-009 for the treatment of solid tumor and hematological cancers with an anticipated IND filing in 1H 2022.

GentiBio Announces $157M Mil Series A Financing

Financing led by Matrix Capital Management with strong investor syndicate, Andy Tran of Matrix Capital to Join GentiBio Board of Directors.

Addex and Indivior Extend Research Collaboration on GABAB Positive Allosteric Modulators – Indivior Commits $4 Million of New Funding

IND enabling studies with Indivior collaboration drug candidate and separate Addex program scheduled for 2022.

DW Healthcare Partners Invests in Bio Agri Mix

DW Healthcare Partners ("DWHP") a healthcare-focused private equity firm, announced the completion of its investment in Bio Agri Mix, LP ("Bio Agri Mix" or the "Company"). Bio Agri Mix is Canada's largest manufacturer and distributor of medicated feed additives and...

Lumira Ventures Closes on US $255 Mil of New Capital

Oversubscribed Lumira Ventures IV to continue successful focus backing biotechnology and medtech companies in Canada and U.S. Companion strategic fund formed in partnership with international pharmaceutical company. During the past 18 months, Lumira Ventures completed 8 exit transactions and portfolio companies received 2 FDA new product approvals and raised over US$800M via IPOs and public and private financings.

AXA IM Alts Raises €1.9 Billion for European Life Sciences Investments

Isabelle Scemama, Global Head of AXA IM Alts & CEO of AXA IM - Real Assets, commented: “The success of this capital raise underlines our ability to present our clients with opportunities to invest at scale in our key conviction asset classes, such as life sciences, which offer sustainable and growing income returns over the long term.

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

Biospectal will leverage the new funds to scale its OptiBP™ smartphone blood pressure monitoring application and data platform technology worldwide. Biospectal OptiBP for Android launched in public beta in January 2021.
spot_img

Latest News

Accuredit Therapeutics and N1 Life Form a Joint Venture Named ‘Napoltec’, Dedicated to the Development of Therapeutic Drug Delivery Systems and Pressing Ahead Clinical...

"We are very pleased to establish a new joint venture, Napoltec, with N1 Life, which will be featuring complementary in mutually pursuing gene therapy drug development. The N1 Life team led by Dr. Zang and Prof. Wender has accumulated years of research and development experience in novel delivery systems.

FDA Releases Federal Interagency Working Group Scientific Opinions on Testing Methods for Asbestos in Talc-Containing Cosmetic Products

Release of the white paper concludes the efforts of the IWGACP. The FDA will consider the scientific opinions presented in the white paper, including having it peer-reviewed, as part of its overall efforts to help ensure the safety of talc-containing cosmetic products.

Hekka Labs Introduces the First Decentralized Chronic Disease Data Management Ecosystem in South Asia

Hekka has cemented initial partnerships with 3 Indian healthcare solution providers, Curisin, a healthcare company with a wide network of 30 million patients and 40,000 partnered doctors which as recently agreed to provide a minimum of 1.5 million medical records in 2022.

Impact NRS LLC Creates RumenEra Inc to Develop and Commercialize High-Impact Rumen Microbiome Applications in a Joint Collaboration with National Institute for Biotechnology in...

Mr. Salman continues "RumenEra is committed to the creation of a global reference standard for the rapid measurement of net feed efficiency, as well as creating products that can be applied to ruminants to optimize their efficiency while decreasing environmental burdens, naturally and healthily, for both the animals and their ecosystems."

Join Medical Device News Magazine's Mailing List: Receive a Weekly Recap of Device Industry News

spot_img